Objective To investigate the effects of bortezomib on immune function and renal function in patients with multiple myeloma.Method A total of 70 patients with multiple myeloma were divided into vincristine group(n=34,vincristine combined with dexamethasone and thalidomide)and bortezomib group(n=36,bortezomib combined with dexamethasone and thalidomide)according to different treatment methods.The clinical efficacy,immune function index-es(CD3+,CD4+,CD8+,CD4+/CD8+),renal function indexes[blood urea nitrogen(BUN),serum creatinine(SCr)],M pro-tein level and number of myeloma cells were compared between the two groups.Result The total effective rate of bort-ezomib group was higher than that of vincristine group,and the difference was statistically significant(P＜0.05).After treatment,the CD3+,CD4+,SCr,BUN levels and CD4+/CD8+in two groups were higher than those before treatment,the CD8+and M protein levels were lower than those before treatment,the number of myeloma cells were less than those be-fore treatment,the CD3+,CD4+levels and CD4+/CD8+in bortezomib group were higher than those in vincristine group,the CD8+,SCr,BUN and M protein levels were lower than those in vincristine group,the number of myeloma cells was less than that in vincristine group,and the differences were statistically significant(P＜0.05).Conclusion Bortezomib combined with dexamethasone and thalidomide can improve immune function in patients with multiple myeloma,inhibit M protein and myeloma cell generation,enhance clinical efficacy,and have less damage to renal function.
维普
万方数据
